Eugit Therapeutics

Eugit Therapeutics addresses the critical challenge of non-specific drug delivery, a major contributor to toxicity and clinical trial failures, particularly impacting individuals suffering from tissue-specific inflammatory diseases. Their innovative TAGHOME technology enables precise drug targeting to diseased tissues by leveraging T cell receptors. This targeted approach aims to significantly enhance drug safety and improve therapeutic efficacy. The company's initial focus is on addressing Inflammatory Bowel Disease (IBD), which affects an estimated 3.1 million people in the United States. Eugit Therapeutics plans to initiate clinical trials within the next two years, marking a significant step towards bringing targeted therapies to patients in need. Founded by George Church of Harvard University and backed by Y Combinator (S22), Eugit Therapeutics is poised to revolutionize drug delivery in the treatment of inflammatory diseases.